{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:24:49Z","timestamp":1792070689577,"version":"4.4.0"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000971","name":"Diabetes Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.yjmcc.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:39:48Z","timestamp":1768376388000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy"],"prefix":"10.1016","volume":"213","author":[{"given":"Monica","family":"Kanki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes mellitus, the fastest growing global public health concern: early detection should be focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Sci. Rep."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes\u2013global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Global Health"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2022.06.003","article-title":"Adult-onset type 1 diabetes: A changing perspective","volume":"104","author":"Burahmah","year":"2022","journal-title":"Eur. J. Intern. Med."},{"issue":"Supplement_1","key":"10.1016\/j.yjmcc.2026.01.004_bb0020","first-page":"S17","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142022","volume":"45","author":"Committee","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0025","first-page":"401","article-title":"Type 2 diabetes mellitus in children and adolescents","volume":"45","author":"Kao","year":"2016","journal-title":"Aust. Fam. Physician"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0030","doi-asserted-by":"crossref","DOI":"10.2174\/1573399817666210503133747","article-title":"Why is the incidence of type 1 diabetes increasing?","volume":"17","author":"Abela","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"16","key":"10.1016\/j.yjmcc.2026.01.004_bb0040","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","article-title":"Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults","volume":"78","author":"Segar","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2_suppl","key":"10.1016\/j.yjmcc.2026.01.004_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13098-023-00998-y","article-title":"Potential clinical biomarkers and perspectives in diabetic cardiomyopathy","volume":"15","author":"Deng","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1042\/EBC20210006","article-title":"Mineralocorticoid receptor actions in cardiovascular development and disease","volume":"65","author":"Young","year":"2021","journal-title":"Essays Biochem."},{"issue":"19","key":"10.1016\/j.yjmcc.2026.01.004_bb0060","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1136\/heartjnl-2020-318811","article-title":"Management of heart failure with reduced ejection fraction","volume":"108","author":"Haydock","year":"2022","journal-title":"Heart"},{"issue":"17","key":"10.1016\/j.yjmcc.2026.01.004_bb0065","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0070","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coph.2020.10.007","article-title":"Corticosteroids and circadian rhythms in the cardiovascular system","volume":"57","author":"Kanki","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0080","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1210\/en.2016-1911","article-title":"Deoxycorticosterone\/salt-mediated cardiac inflammation and fibrosis are dependent on functional CLOCK Signaling in male mice","volume":"158","author":"Fletcher","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0085","series-title":"Cardiorenal Heart Failure With Preserved Ejection Fraction is Caused by a Reversible Rise of Mineralocorticoid-Induced Fibroblast Subtypes","article-title":"S. Preissl","author":"Lother","year":"2025"},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0090","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0506-x","article-title":"Diagnostic approaches for diabetic cardiomyopathy","volume":"16","author":"Lorenzo-Almor\u00f3s","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0100","article-title":"Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies","volume":"23","author":"Rizza","year":"2024","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.1991.03460050081025","article-title":"Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men?: the rancho Bernardo study","volume":"265","author":"Barrett-Connor","year":"1991","journal-title":"Jama"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","article-title":"Gender differences in coronary heart disease","volume":"18","author":"Maas","year":"2010","journal-title":"Neth. Hear. J."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00125-020-05319-w","article-title":"Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses","volume":"64","author":"Nanayakkara","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0125","series-title":"Health, Welfare, Cardiovascular Disease, Diabetes and Chronic Kidney Disease\u2014Australian Facts: Aboriginal and Torres Strait Islander People 2015","author":"A.I.o.","year":"2015"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0130","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/697240","article-title":"Diabetes and coronary heart disease: a risk factor for the global epidemic","volume":"2012","author":"Chiha","year":"2012","journal-title":"Int. J. Hypertens."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"1, Part A","key":"10.1016\/j.yjmcc.2026.01.004_bb0140","doi-asserted-by":"crossref","first-page":"102052","DOI":"10.1016\/j.cpcardiol.2023.102052","article-title":"Diabetic cardiomyopathy: 2023 update by the international multidisciplinary board of experts","volume":"49","author":"Avagimyan","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0145","first-page":"690","article-title":"Glycated haemoglobin - a marker and predictor of cardiovascular disease","volume":"61","author":"Syed","year":"2011","journal-title":"J. Pak. Med. Assoc."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated Hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0155","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11892-013-0380-1","article-title":"Is the risk and nature of CVD the same in type 1 and type 2 diabetes?","volume":"13","author":"Duca","year":"2013","journal-title":"Curr. Diab. Rep."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-020-0334-z","article-title":"Young-onset type 2 diabetes mellitus\u2014implications for morbidity and mortality","volume":"16","author":"Magliano","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.01.004_bb0165","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/imj.13792","article-title":"Prevalence of diabetes in Australia: insights from the Fremantle diabetes study phase II","volume":"48","author":"Davis","year":"2018","journal-title":"Intern. Med. J."},{"issue":"12","key":"10.1016\/j.yjmcc.2026.01.004_bb0170","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.2337\/dc12-2455","article-title":"Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes","volume":"36","author":"Constantino","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.0686","article-title":"Association of Type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and Young adulthood","volume":"317","author":"Dabelea","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-nutr-080508-141200","article-title":"Management of the metabolic syndrome and type 2 diabetes through lifestyle modification","volume":"29","author":"Magkos","year":"2009","journal-title":"Annu. Rev. Nutr."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjaed\/mkw075","article-title":"Diabetes medication pharmacology","volume":"17","author":"Stubbs","year":"2017","journal-title":"BJA Edu."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0190","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0925-y","article-title":"Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation","volume":"18","author":"Ram","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"21","key":"10.1016\/j.yjmcc.2026.01.004_bb0200","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01202-5","article-title":"Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0210","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: A methodological Meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","article-title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","volume":"3","author":"Simpson","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0220","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00125-006-0176-9","article-title":"Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin","volume":"49","author":"Evans","year":"2006","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0225","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.2337\/dc08-0167","article-title":"Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies","volume":"31","author":"Rao","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d1309","article-title":"Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies","volume":"342","author":"Loke","year":"2011","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0235","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diabetes.53.1.5","article-title":"Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic \u03b2-cell","volume":"53","author":"Holz","year":"2004","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10157","key":"10.1016\/j.yjmcc.2026.01.004_bb0250","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.yjmcc.2026.01.004_bb0255","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10193","key":"10.1016\/j.yjmcc.2026.01.004_bb0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0265","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0270","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0275","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.yjmcc.2026.01.004_bb0280","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-019-0293-y","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis","volume":"20","author":"Liu","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0290","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ehf2.12079","article-title":"Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus","volume":"3","author":"Sato","year":"2016","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hrtlng.2023.02.009","article-title":"SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: a meta-analysis of randomized controlled trials","volume":"59","author":"He","year":"2023","journal-title":"Heart Lung"},{"issue":"10166","key":"10.1016\/j.yjmcc.2026.01.004_bb0305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0310","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.09.005","article-title":"SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus","volume":"47","author":"Wong","year":"2021","journal-title":"Diabetes Metab."},{"issue":"12","key":"10.1016\/j.yjmcc.2026.01.004_bb0320","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jacc.2024.06.036","article-title":"Effects of Sotagliflozin on health status in patients with worsening heart failure: results from SOLOIST-WHF","volume":"84","author":"Bhatt","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0330","first-page":"10.2215","article-title":"Sotagliflozin and kidney outcomes, kidney function, and albuminuria in T2DM and CKD: a secondary analysis of the SCORED trial","author":"Sridhar","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0335","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0340","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0345","doi-asserted-by":"crossref","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0350","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr. Physiol."},{"issue":"Volume 86, 2024","key":"10.1016\/j.yjmcc.2026.01.004_bb0355","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","article-title":"The mineralocorticoid receptor in the vasculature: friend or foe?","volume":"86","author":"Ibarrola","year":"2024","journal-title":"Annu. Rev. Physiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0360","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/HYPERTENSIONAHA.108.114223","article-title":"Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes","volume":"52","author":"Rossier","year":"2008","journal-title":"Hypertension"},{"issue":"4812","key":"10.1016\/j.yjmcc.2026.01.004_bb0365","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0370","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.2000.00978.x","article-title":"Role of the 11\u03b2-hydroxysteroid dehydrogenase type 2 in blood pressure regulation","volume":"57","author":"Ferrari","year":"2000","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0375","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2013-2049","article-title":"Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist","volume":"99","author":"Iqbal","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0380","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"Mihailidou","year":"2009","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0385","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2009.12.003","article-title":"Aldosterone and mineralocorticoid receptors in the cardiovascular system","volume":"52","author":"J.W. Funder","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0390","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0395","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-14-0471","article-title":"Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals","volume":"224","author":"Young","year":"2015","journal-title":"J. Endocrinol."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0400","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.bbadis.2016.10.025","article-title":"Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction","volume":"1863","author":"Jia","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.694758","article-title":"The cardiac mineralocorticoid receptor (MR): a therapeutic target against ventricular arrhythmias","volume":"12","author":"Rossier","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.01.004_bb0410","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/CS20140758","article-title":"Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus","volume":"129","author":"Silva","year":"2015","journal-title":"Clin. Sci."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0415","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bjp.0704131","article-title":"Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats","volume":"133","author":"Miric","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-12-172","article-title":"Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes","volume":"12","author":"Ram\u00edrez","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0425","first-page":"2810","article-title":"Eplerenone attenuates myocardial infarction in diabetic rats via modulation of the PI3K-Akt pathway and phosphorylation of GSK-3\u03b2","volume":"10","author":"Mahajan","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0430","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115661","article-title":"Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors","volume":"168","author":"Sanz-G\u00f3mez","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0440","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","article-title":"Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0445","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2220\/biomedres.46.83","article-title":"Finerenone alleviates the high glucose-induced fibrosis in HK-2 cells by inhibiting EMT via the TGF-\u03b21\/Smads signaling","volume":"46","author":"Wang","year":"2025","journal-title":"Biomed. Res."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0450","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphys.2015.00269","article-title":"Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO\/GC signaling","volume":"6","author":"Silva","year":"2015","journal-title":"Front. Physiol."},{"issue":"12","key":"10.1016\/j.yjmcc.2026.01.004_bb0455","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3390\/cells8121595","article-title":"NLRP3 inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus","volume":"8","author":"Ferreira","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.yjmcc.2026.01.004_bb0460","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short-and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.yjmcc.2026.01.004_bb0465","first-page":"923","article-title":"Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K\/Akt and p38MAPK signaling pathways","volume":"36","author":"Long","year":"2013","journal-title":"J. Endocrinol. Investig."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0470","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13731","article-title":"Endothelial mineralocorticoid receptor ablation confers protection towards endothelial dysfunction in experimental diabetes in mice","volume":"234","author":"Lyngs\u00f8","year":"2022","journal-title":"Acta Physiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0475","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/HYPERTENSIONAHA.115.06172","article-title":"Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure","volume":"66","author":"Barrett Mueller","year":"2015","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0480","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/HYPERTENSIONAHA.115.06015","article-title":"Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females","volume":"66","author":"Jia","year":"2015","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0485","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0490","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2014.348","article-title":"Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans","volume":"87","author":"Hosoya","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115910","article-title":"Sex-dependent effects of finerenone on hemostasis in normoglycemic and streptozotocin-induced diabetic mice","volume":"169","author":"Natalia","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0500","doi-asserted-by":"crossref","DOI":"10.1097\/FJC.0b013e3181be75cc","article-title":"Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes","volume":"54","author":"Goyal","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0505","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cardfail.2012.03.002","article-title":"Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS","volume":"18","author":"Ukena","year":"2012","journal-title":"J. Card. Fail."},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0510","doi-asserted-by":"crossref","first-page":"H1126","DOI":"10.1152\/ajpheart.00898.2014","article-title":"Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice","volume":"308","author":"Bostick","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0515","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1210\/en.2008-0239","article-title":"The Heme oxygenase system abates Hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways","volume":"150","author":"Ndisang","year":"2009","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.yjmcc.2026.01.004_bb0520","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1210\/en.2016-1358","article-title":"Aldosterone synthase inhibition improves glucose tolerance in Zucker diabetic fatty (ZDF) rats","volume":"157","author":"Hofmann","year":"2016","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0525","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13098-024-01525-3","article-title":"Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes","volume":"16","author":"Tran","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0530","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/db16-1354","article-title":"Deletion of macrophage mineralocorticoid receptor protects hepatic steatosis and insulin resistance through ER\u03b1\/HGF\/met pathway","volume":"66","author":"Zhang","year":"2017","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0535","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/CIRCRESAHA.109.209957","article-title":"The cardiomyocyte circadian clock: emerging roles in health and disease","volume":"106","author":"Durgan","year":"2010","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0540","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1172\/JCI10583","article-title":"Cellular mechanisms of insulin resistance","volume":"106","author":"Shulman","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0545","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411002109","article-title":"PI3K\/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis","volume":"14","author":"Schultze","year":"2012","journal-title":"Expert Rev. Mol. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.01.004_bb0550","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00210-019-01641-2","article-title":"Aldosterone stimulation mediates cardiac metabolism remodeling via Sirt1\/AMPK signaling in canine model","volume":"392","author":"Liu","year":"2019","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"12","key":"10.1016\/j.yjmcc.2026.01.004_bb0555","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.3390\/biomedicines11123319","article-title":"Esaxerenone protects against diabetic cardiomyopathy via inhibition of the chemokine and PI3K-akt signaling pathway","volume":"11","author":"Li","year":"2023","journal-title":"Biomedicines"},{"issue":"1\u20132","key":"10.1016\/j.yjmcc.2026.01.004_bb0560","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000528783","article-title":"Mineralocorticoid receptor-associated mechanisms in diabetic kidney disease and clinical significance of mineralocorticoid receptor antagonists","volume":"54","author":"Mende","year":"2023","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0565","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/bbrc.1995.2106","article-title":"Rapid aldosterone Signaling in vascular smooth-muscle cells-involvement of phospholipase-C, diacylglycerol and protein-kinase-C-\u03b1","volume":"213","author":"Christ","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.yjmcc.2026.01.004_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100449","article-title":"Brown adipocyte mineralocorticoid receptor deficiency impairs metabolic regulation in diet-induced obese mice","volume":"64","author":"Chen","year":"2023","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0575","first-page":"4033","article-title":"Aldosterone promotes renal interstitial fibrosis via the AIF-1\/AKT\/mTOR signaling pathway","volume":"20","author":"Yuan","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0580","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1111\/j.1440-1797.2005.00455.x","article-title":"Role of aldosterone in diabetic nephropathy","volume":"10","author":"Cha","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102946","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","volume":"68","author":"Yao","year":"2023","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0590","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160086","article-title":"Spironolactone promotes autophagy via inhibiting PI3K\/AKT\/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress","volume":"36","author":"Li","year":"2016","journal-title":"Biosci. Rep."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0595","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1096\/fj.13-245415","article-title":"Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice","volume":"28","author":"Armani","year":"2014","journal-title":"FASEB J."},{"issue":"17","key":"10.1016\/j.yjmcc.2026.01.004_bb0600","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-\u03b3, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0605","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00018-023-04899-1","article-title":"Interference of a mammalian circRNA regulates lipid metabolism reprogramming by targeting miR-24-3p\/Igf2\/PI3K-AKT-mTOR and Igf2bp2\/Ucp1 axis","volume":"80","author":"Shao","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"issue":"18","key":"10.1016\/j.yjmcc.2026.01.004_bb0610","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.18632\/aging.102263","article-title":"MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-\u03b3-mediated PI3K\/AKT signaling","volume":"11","author":"Chen","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0615","doi-asserted-by":"crossref","first-page":"23957","DOI":"10.1038\/srep23957","article-title":"Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0620","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41440-022-01036-6","article-title":"Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification","volume":"46","author":"Jo","year":"2023","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0625","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2010.04.149","article-title":"Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity","volume":"396","author":"Matsui","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.yjmcc.2026.01.004_bb0630","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bbamem.2017.01.018","article-title":"Glycosylation of voltage-gated calcium channels in health and disease","volume":"1859","author":"Lazniewska","year":"2017","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0635","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2974304","article-title":"Calcium signaling in the ventricular myocardium of the Goto-Kakizaki type 2 diabetic rat","volume":"2018","author":"Al Kury","year":"2018","journal-title":"J. Diabetes Res."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0640","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/biomedicines9080946","article-title":"Aldosterone excess induced mitochondria decrease and dysfunction via mineralocorticoid receptor and oxidative stress in vitro and in vivo","volume":"9","author":"Tsai","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0645","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9232065","article-title":"Spironolactone protects against diabetic cardiomyopathy in streptozotocin-induced diabetic rats","volume":"2018","author":"Liu","year":"2018","journal-title":"J. Diabetes Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0650","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejn.14255","article-title":"Circadian disruption: what do we actually mean?","volume":"51","author":"Vetter","year":"2020","journal-title":"Eur. J. Neurosci."},{"issue":"458","key":"10.1016\/j.yjmcc.2026.01.004_bb0655","doi-asserted-by":"crossref","first-page":"eaat8806","DOI":"10.1126\/scitranslmed.aat8806","article-title":"A database of tissue-specific rhythmically expressed human genes has potential applications in circadian medicine","volume":"10","author":"Ruben","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0660","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fphys.2019.00682","article-title":"New insights into the circadian rhythm and its related diseases","volume":"10","author":"Yanling","year":"2019","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0665","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nm.2061","article-title":"Salt-sensitive hypertension in circadian clock\u2013deficient cry-null mice involves dysregulated adrenal Hsd3b6","volume":"16","author":"Doi","year":"2010","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0670","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.121.056076","article-title":"Myocardial Rev-erb\u2013mediated diurnal metabolic rhythm and obesity paradox","volume":"145","author":"Song","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0675","first-page":"H1036","article-title":"Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression","volume":"294","author":"Bray","year":"2008","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"11","key":"10.1016\/j.yjmcc.2026.01.004_bb0680","first-page":"H1827","article-title":"Cardiomyocyte-specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response, and impaired resolution of inflammation","volume":"309","author":"Ingle","year":"2015","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.01.004_bb0685","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2013060641","article-title":"Local renal circadian clocks control fluid\u2013electrolyte homeostasis and BP","volume":"25","author":"Tokonami","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0690","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.gene.2019.03.038","article-title":"Circadian clock genes and myocardial infarction in patients with type 2 diabetes mellitus","volume":"701","author":"\u0160krlec","year":"2019","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-015-0327-8","article-title":"CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial","volume":"15","author":"Corella","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0700","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2004.03.055","article-title":"Gene-and tissue-specific alterations of circadian clock gene expression in streptozotocin-induced diabetic mice under restricted feeding","volume":"317","author":"Oishi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0705","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/jmcc.2001.1504","article-title":"Alterations of the circadian clock in the heart by streptozotocin-induced diabetes","volume":"34","author":"Young","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102788","article-title":"Bmal1 downregulation leads to diabetic cardiomyopathy by promoting Bcl2\/IP3R-mediated mitochondrial Ca2+ overload","volume":"64","author":"Zhang","year":"2023","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0715","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12378","article-title":"Novel protective role of the circadian nuclear receptor retinoic acid-related orphan receptor-\u03b1 in diabetic cardiomyopathy","volume":"62","author":"Zhao","year":"2017","journal-title":"J. Pineal Res."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0720","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bmcl.2015.12.102","article-title":"Carbazole-containing sulfonamides and sulfamides: discovery of cryptochrome modulators as antidiabetic agents","volume":"26","author":"Humphries","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0725","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-pharmtox-010617-052645","article-title":"Development and therapeutic potential of small-molecule modulators of circadian systems","volume":"58","author":"Chen","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"aop","key":"10.1016\/j.yjmcc.2026.01.004_bb0730","article-title":"Cardiomyocyte transcription is controlled by combined MR and circadian clock signalling","volume":"1","author":"Fletcher","year":"2019","journal-title":"J. Endocrinol."},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0735","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00380-006-0968-3","article-title":"Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts","volume":"22","author":"Tanaka","year":"2007","journal-title":"Heart Vessel."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0740","first-page":"3416","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"(7),","author":"Rickard","year":"2012","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0745","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1463-1326.2007.00730.x","article-title":"Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS","volume":"10","author":"O\u2019Keefe","year":"2008","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.yjmcc.2026.01.004_bb0750","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/ehjci\/jeu013","article-title":"Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy","volume":"15","author":"Jellis","year":"2014","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0755","first-page":"550","article-title":"Mineralocorticoid receptor antagonist improves cardiac structure in type 2 diabetes: data from the MIRAD trial","volume":"9","author":"Brandt-Jacobsen","year":"2021","journal-title":"Heart Failure"},{"issue":"14","key":"10.1016\/j.yjmcc.2026.01.004_bb0760","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0765","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12872-023-03183-1","article-title":"Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial","volume":"23","author":"Brandt-Jacobsen","year":"2023","journal-title":"BMC Cardiovasc. Disord."},{"issue":"3","key":"10.1016\/j.yjmcc.2026.01.004_bb0770","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium\u2013glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int. Rep."},{"issue":"10458","key":"10.1016\/j.yjmcc.2026.01.004_bb0775","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0780","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"10505","key":"10.1016\/j.yjmcc.2026.01.004_bb0785","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(25)01153-5","article-title":"Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"406","author":"Pyne","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.yjmcc.2026.01.004_bb0790","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: A Meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0795","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70080","article-title":"Blood pressure\u2013lowering effects of aldosterone synthase inhibitors\u2014a systematic review","volume":"137","author":"Rasmussen","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.yjmcc.2026.01.004_bb0800","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Pitt eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.yjmcc.2026.01.004_bb0810","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/phar.2633","article-title":"Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI\/ARBs in patients with diabetic kidney disease","volume":"41","author":"An","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"23","key":"10.1016\/j.yjmcc.2026.01.004_bb0815","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0820","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0825","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"16","key":"10.1016\/j.yjmcc.2026.01.004_bb0835","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0840","first-page":"1","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0845","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0850","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"24","key":"10.1016\/j.yjmcc.2026.01.004_bb0855","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.yjmcc.2026.01.004_bb0860","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.yjmcc.2026.01.004_bb0870","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1093\/cvr\/cvac007","article-title":"Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular ageing","volume":"118","author":"Ibarrola","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0875","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30061226","article-title":"In silico investigation of mineralocorticoid receptor antagonists: insights into binding mechanisms and structural dynamics","volume":"30","author":"Liang","year":"2025","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.yjmcc.2026.01.004_bb0880","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/bph.15746","article-title":"Structural and molecular determinants of mineralocorticoid receptor signalling","volume":"179","author":"Grossmann","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0885","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1161\/HYPERTENSIONAHA.118.12162","article-title":"Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing","volume":"73","author":"Fraccarollo","year":"2019","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.yjmcc.2026.01.004_bb0890","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbamem.2015.11.023","article-title":"Mineralocorticoid receptor mediated liposomal delivery system for targeted induction of apoptosis in cancer cells","volume":"1858","author":"Sharma","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.yjmcc.2026.01.004_bb0895","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/dc11-0297","article-title":"Influence of time of day of blood pressure\u2013lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes","volume":"34","author":"Hermida","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0900","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/HYPERTENSIONAHA.107.096933","article-title":"Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension","volume":"51","author":"Hermida","year":"2008","journal-title":"Hypertension"},{"issue":"48","key":"10.1016\/j.yjmcc.2026.01.004_bb0905","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1093\/eurheartj\/ehz754","article-title":"Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial","volume":"41","author":"Hermida","year":"2019","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.yjmcc.2026.01.004_bb0910","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1093\/eurjpc\/zwac085","article-title":"Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials","volume":"29","author":"Maqsood","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2020.10.014","article-title":"Chronotherapy of cardiac and vascular disease: timing medications to circadian rhythms to optimize treatment effects and outcomes","volume":"57","author":"Smolensky","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0920","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejim.2013.03.019","article-title":"Circadian rhythms and medical diseases: does it matter when drugs are taken?","volume":"24","author":"De Giorgi","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.yjmcc.2026.01.004_bb0925","article-title":"Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia","volume":"11","author":"Izquierdo-Palomares","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.yjmcc.2026.01.004_bb0930","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0000000000003240","article-title":"Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by world hypertension league and European Society of Hypertension","volume":"40","author":"Stergiou","year":"2022","journal-title":"J. Hypertens."},{"issue":"45","key":"10.1016\/j.yjmcc.2026.01.004_bb0935","doi-asserted-by":"crossref","first-page":"16219","DOI":"10.1073\/pnas.1408886111","article-title":"A circadian gene expression atlas in mammals: implications for biology and medicine","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"701","key":"10.1016\/j.yjmcc.2026.01.004_bb0940","doi-asserted-by":"crossref","first-page":"eadg8464","DOI":"10.1126\/scitranslmed.adg8464","article-title":"High-resolution daily profiles of tissue adrenal steroids by portable automated collection","volume":"15","author":"Upton","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0945","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0950","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.yjmcc.2026.01.004_bb0955","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0960","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J. Card. Fail."},{"issue":"27","key":"10.1016\/j.yjmcc.2026.01.004_bb0965","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0970","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"10518","key":"10.1016\/j.yjmcc.2026.01.004_bb0975","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","article-title":"Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial","volume":"406","author":"Heerspink","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.yjmcc.2026.01.004_bb0980","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/bcp.70017","article-title":"The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone","volume":"91","author":"Bhattacharya","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb0985","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.kisu.2021.11.001","article-title":"Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms","volume":"12","author":"Bauersachs","year":"2011","journal-title":"Kidney Int. Suppl."},{"issue":"16","key":"10.1016\/j.yjmcc.2026.01.004_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by Finerenone-translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.yjmcc.2026.01.004_bb0995","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/life14080967","article-title":"Esaxerenone attenuates aldosterone-induced mitochondrial damage-mediated pyroptosis in mouse aorta and rat vascular smooth muscle cells","volume":"14","author":"Xian","year":"2024","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.yjmcc.2026.01.004_bb1000","doi-asserted-by":"crossref","first-page":"26266","DOI":"10.1038\/s41598-024-78321-6","article-title":"Effect of esaxerenone on the onset of aortic endothelial dysfunction and circulating microparticles in type 1 diabetic male mice","volume":"14","author":"Taguchi","year":"2024","journal-title":"Sci. Rep."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282826000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282826000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:58:03Z","timestamp":1779004683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282826000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":200,"alternative-id":["S0022282826000040"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2026.01.004","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}